2023
Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept
Aminu M, Daver N, Godoy M, Shroff G, Wu C, Torre-Sada L, Goizueta A, Shannon V, Faiz S, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim S, Kontoyiannis D, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Frontiers In Immunology 2023, 14: 1249511. PMID: 37841255, PMCID: PMC10570510, DOI: 10.3389/fimmu.2023.1249511.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsGround-glass opacitiesBlood biomarkersImmune checkpoint inhibitor pneumonitisCheckpoint inhibitor pneumonitisAcute myeloid leukemiaPost-test probabilityCheckpoint inhibitorsMyeloid leukemiaCT patternsLung inflammationPneumonitisInfected lungsRelevant blood biomarkersDiagnostic valueLung parenchymaPneumoniaCT imagesBloodBiomarkersPatientsHabitat imagesBlood modelDetection of pneumoniaLeukemia
2019
Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare
Kim S, Bittar M, Kim H, Neelapu S, Zurita A, Nurieva R, Suarez-Almazor M. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. Journal For ImmunoTherapy Of Cancer 2019, 7: 126. PMID: 31088575, PMCID: PMC6518723, DOI: 10.1186/s40425-019-0597-x.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsNivolumab infusionAdverse eventsIL-17 producing CD4Immune checkpoint inhibitor therapyImmune checkpoint inhibitor treatmentImmune-related adverse eventsPatients treated with nivolumabCD4+ T cellsAmount of IL-17Characterized immune cellsCheckpoint inhibitor treatmentPD-1 inhibitorsCheckpoint inhibitor therapyCrystal arthritisSynovial fluidRenal cell carcinomaAutoimmune inflammatory arthritisT helper 17Neutrophil-driven inflammationProphylactic colchicinePD-1Inhibitor therapyConclusionsThis caseEx Vivo Interferon Gamma Production by Peripheral Immune Cells Predicts Survival in Lung Adenocarcinoma
Ahn S, Kwon M, Sung M, Jung S, Lee S, Park Y, Kim S, Song J. Ex Vivo Interferon Gamma Production by Peripheral Immune Cells Predicts Survival in Lung Adenocarcinoma. Clinical Lung Cancer 2019, 20: e299-e308. PMID: 30824332, DOI: 10.1016/j.cllc.2019.01.002.Peer-Reviewed Original ResearchConceptsIFN-g productionEastern Cooperative Oncology Group performance statusIFN-gLung adenocarcinomaOverall survivalPerformance statusLung cancerAssociated with lung cancer pathogenesisCancer stageProduction of IFN-gReceiver operating characteristic curve analysisStage IV lung cancerCox proportional hazards analysisTreatment-naive patientsAntitumor immune surveillanceOperating characteristics curve analysisOptimal cutoff valueOverall patient survivalInterferon-gamma productionCharacteristic curve analysisIFN-g levelsIV lung cancerProportional hazards analysisStage IV cancerLung cancer pathogenesis